Introduction
============

Anxiety disorders in epilepsy can be classified according to the temporal relationship with the ictal event. Preictal anxiety precedes the onset of seizures by hours or days ([@b14-ndt-4-1235]). Postictal fear can last up to 7 days after the seizure. In ictal anxiety, nervousness, fear, anger and irritability can be a partial seizure or an "aura" of a complex partial seizure ([@b9-ndt-4-1235]); especially among patients with temporal lobe epilepsy (TLE) (10%--15% with lateral foci and 15%--20% with medial foci) ([@b10-ndt-4-1235]; [@b6-ndt-4-1235]). Ictal foci on other locations have been related to ictal fear ([@b12-ndt-4-1235]). Interictal anxiety is defined as the presence of anxiety symptoms without temporal relationship with seizures ([@b12-ndt-4-1235]). It can manifest as clinical anxiety disorders such as panic disorder, general anxiety disorder, or obsessive compulsive disorder ([@b21-ndt-4-1235]).

The prevalence of interictal anxiety in epilepsy varies among the type of sample studied. Anxiety has been found in 10%--25% of patients with epilepsy in the community ([@b8-ndt-4-1235]; [@b11-ndt-4-1235]; [@b15-ndt-4-1235]); in 19% of TLE ([@b5-ndt-4-1235]) and in 24.7% in surgical candidates ([@b7-ndt-4-1235]). It is more severe among patients with focal epilepsy ([@b11-ndt-4-1235]) and more frequent compared with normal controls and patients with other chronic diseases ([@b22-ndt-4-1235]; [@b17-ndt-4-1235]; [@b9-ndt-4-1235]).

The origin and type of seizures ([@b23-ndt-4-1235]), the diagnosis of temporal lobe epilepsy with amygdala involvement ([@b24-ndt-4-1235]), the use of antiepileptic drugs ([@b19-ndt-4-1235]; [@b20-ndt-4-1235]), and psychological factors ([@b13-ndt-4-1235]) have been related to the development of anxiety in patients with epilepsy.

However, there is less information regarding which symptoms are related to seizures and which ones are due to anxiety itself.

We performed the present study to determine the frequency of anxiety in patients with epilepsy in order to discover which symptoms of anxiety were the most frequently reported in patients with epilepsy and to analyze the factors associated with its development.

Methods
=======

We conducted a cross-sectional survey in all consecutive outpatients with epilepsy, defined as recurrent seizures, who attended the National Institute of Neurology of Mexico between September 2006 and March 2007. Patients with symptomatic epilepsy secondary to brain neoplasms, vascular malformations, neurocysticercosis (in all patients with diagnosis of mesial temporal sclerosis, one or more magnetic resonance imaging (MRI) scans were performed to rule out neurocysticercosis), other cerebral infections, cerebrovascular disease, or mental retardation, were excluded as well as patients with a seizure occurring the day of the research interview, or the day before. No patient received antidepressants or antipsychotic medication, and no patient had a prior diagnosis of anxiety or depression. A structured, *ad hoc* questionnaire was used to register demographical and clinical data. We classified patients in primary generalized and partial epilepsy based on the clinical features of seizures according to the International League Against Epilepsy Classification of Epileptic Seizures ([@b3-ndt-4-1235]) and supported by the electroencephalogram (EEG) findings. Patients that were classified as primary generalized epilepsy had generalized seizures and generalized epilpetiform activity; while those patients with simple partial, complex-partial and partial-onset secondary generalized seizures and/or focal epileptiform activity were classified as having partial epilepsy.

Patients were assessed with the Beck Depression Inventory (BDI) and Montgomery-Asberg Depression Rating Scale (MADRS), and were classified as having a depressive syndrome when both scales indicated so by means of standard cut-off points (14 points in the BDI and 20 points in the MADRS).

The Hamilton Anxiety Scale (HAMA) was assessed by a clinical neuropsychiatrist. Patients were classified as having an anxiety syndrome when the scale indicated so by means of a standard cut-off point (18 points). The diagnosis of generalized anxiety disorder was confirmed according to DSM-IV criteria using a semistructured interview performed by a neuropsychiatrist.

A consent form was obtained for all cases, signed by the patient and two family members, as required by the institutional Ethics Committee.

The data analysis was performed with the SPSS version 10 (SPSS Inc., Chicago, IL) program, including descriptive statistics, normality tests, and a bivariate analysis with the use of Pearson's chi-square tests, Mann Whitney tests, and t-tests. A logistic regression model was constructed taking anxiety syndrome as dependent variable and all variables significant in the previous bivariate analysis as independent ones (p \< 0.05) in order to control for possible confounding variables.

Results
=======

A total of 196 patients were included during a one year period. 54.1% were male and 45.9% were women. The mean age of the total sample was 28 ± 7 years. 40.8% of the patients were married, and 37.8% had a remunerated job.

Regarding the clinical aspects of epilepsy: 35.7% of cases were classified as cryptogenic (defined as epilepsy without an structural lesion, without family history, and without studies to determine a possible genetic syndrome); 18.4% were genetic (those patients with a confirmed genetic syndrome and family history); 14.8% were related to obstetric complications; 11.2% were secondary to medial temporal lobe sclerosis; 10.2% were posttraumatic; and 9.7% were associated with congenital malformations (structural lesions without family history and not related to obstetric complications, as cortical dysplasia or focal gliosis). The length of disease was variable, with a median of 17 years, range 1--45. The mean age of onset of seizures was 11.3 years (SD 7.9 years). The mean frequency of seizures was 12.5 (SD 27.95) events in the past year. Only 23.5% of patients had a good seizure control, defined for purposes of this study as no seizures in the past year; while poor seizure control was defined as one or more seizures in the past year. Patients with polytherapy were 71.9% of sample. The most commonly used drug was phenytoin (59.2%), followed by carbamazepine (55.1%), primidone (31.1%), valproic acid (26.5%), lamotrigine (6.6%), and others.

According to both scales (BDI and MADRS) 42.3% of the patients were considered depressed. The HAMA ratings revealed that 38.8% experienced significant anxiety symptoms, as defined by a rating above 18 points. The symptoms most frequently reported as positive (items with a score different than 0) among all included patients, and among those diagnosed with clinically significant anxiety are reported in [Table 1](#t1-ndt-4-1235){ref-type="table"}.

There were no differences between anxious and nonanxious patients with epilepsy, regarding gender, marital status, or economical activity. Among the clinical variables, depression, posttraumatic epilepsy, educational degree, polytherapy, use of primidone, and inadequate seizure control were related to the presence of significant anxiety symptoms in the bivariate analysis; but only use of primidone, depression, cryptogenic, and posttraumatic etiologies significantly predicts anxiety among our patients after logistic regression as shown in [Table 2](#t2-ndt-4-1235){ref-type="table"}. We did not find association between duration of epilepsy, age of onset, and the frequency of partial complex seizures or temporal epilepsy with anxiety among our patients.

Discussion
==========

In our study, nearly 40% of our patients had self-reported moderate or severe anxiety. This high frequency could be related to the clinical setting, since our institution is a referral center where the majority of patients have refractory epilepsy. However, socioeconomic factors related to lower quality of life, previously reported in Mexican patients ([@b1-ndt-4-1235]) could play a role in this high frequency of anxiety.

Among our patients, depression was the most important predictor of anxiety. The association between anxiety and depression (78% in our population) was very common, and has been reported in other studies ([@b4-ndt-4-1235]). This is an important matter in the clinical practice, since depressive-anxious patients are at increased risk for hospitalization, suicide attempt, a more chronic course, and impairment compared to patients with only depression ([@b26-ndt-4-1235]). The recognition of the comorbidity must be stressed, since it could modify the clinicians' decision for therapy in these patients.

Temporal lobe epilepsy and some antiepileptic drugs, especially topiramate ([@b20-ndt-4-1235]) have been related with interictal anxiety. In our study, anxiety was not associated with temporal lobe epilepsy, and the only medication associated with anxiety among our patients was primidone, fact that could be related to their association with depression, described before ([@b18-ndt-4-1235]). However, the design of the study does not allow us to determine the influence of antiepileptic medication in the outcome of our study.

Another interesting fact was the association between cryptogenic and posttraumatic epilepsies the presence of anxiety in patients with cryptogenic epilepsy could be related both to psychological reactions from the uncertainty of the cause; and neurobiological factors described for the postconcussion syndrome in the posttraumatic epilepsy.

In our patients, the most common isolated symptom of anxiety reported was the presence of fears, but symptoms that differentiate between patients with and without anxiety were anxious mood, tension, insomnia, intellectual function, depressed mood, cardiovascular symptoms, genitourinary symptoms and anxious behavior. This finding suggests that the effect of somatic symptoms on the frequency of anxiety in patients with epilepsy is modest, something previously reported among other patients with complex physical illness and disability ([@b25-ndt-4-1235]). Since the fears item of the HAMA scale is evaluated according to the presence of fears to being left alone, of crowds and of strangers among others, we think that patients with epilepsy, due to their fear to have a seizure in different settings, with different people and for that to be discriminated, could be the main reason why this item was uninformative here.

Assessment of anxiety disorders in epilepsy is difficult because anxiety symptoms such as fear are part of the seizure itself ([@b14-ndt-4-1235]) and because of the overlap between depression and anxiety symptoms ([@b2-ndt-4-1235]). However, all health-related quality of life domains have been found to be significantly worse with the presence of anxiety symptoms independently of the presence of depressive symptoms ([@b2-ndt-4-1235]; [@b4-ndt-4-1235]). Further efforts must be performed in order to build up a specific instrument to diagnose anxiety in this population.

One major flaw in our study is that cross-sectional design does not permit to establish the role of the psychosocial risk factors for anxiety in epilepsy which may include reactions to the unpredictable nature of epilepsy, restrictions in normal living such as driving and employment, lack of financial security and the need to depend on family members. This can lead to low self-esteem, stigmatization and social rejection ([@b16-ndt-4-1235]). Prospective studies must be performed in the future to determine the evolution of the anxiety among patients with epilepsy.
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###### 

Frequency of reported anxiety symptoms in 196 patients with epilepsy

  HAMA items                  All patients included (N = 196)   Patients with anxiety (N = 76)   Patients without anxiety (N = 120)   p
  --------------------------- --------------------------------- -------------------------------- ------------------------------------ ---------
  Anxious mood                158 (80.6%)                       76 (100%)                        82 (68.3%)                           \<0.001
  Tension                     156 (79.6%)                       76 (100%)                        80 (66.7%)                           \<0.001
  Fears                       177 (90.3%)                       72 (94.7%)                       105 (87.5%)                          0.728
  Insomnia                    140 (71.4%)                       73 (96.1%)                       67 (55.8%)                           \<0.001
  Intellectual function       148 (75.5%)                       72 (94.7%)                       76 (63.3%)                           \<0.001
  Depressed mood              154 (78.6%)                       76 (100%)                        78 (65%)                             \<0.001
  Muscular complaints         150 (76.5%)                       60 (78.9%)                       90 (75%)                             0.525
  Sensory complaints          158 (80.6%)                       66 (86.8%)                       92 (76.7%)                           0.079
  Cardiovascular symptoms     83 (42.3%)                        41 (53.9%)                       42 (35%)                             0.009
  Respiratory symptoms        81 (41.3%)                        38 (50%)                         43 (35.8%)                           0.054
  Gastrointestinal symptoms   57 (29.1%)                        19 (25%)                         38 (31.7%)                           0.317
  Genitourinary symptoms      174 (88.8%)                       74 (97.4%)                       100 (83.3%)                          0.002
  Autonomic symptoms          116 (59.2%)                       45 (59.2%)                       71 (59.2%)                           0.995
  Anxious behavior            158 (80.6%)                       76 (100%)                        82 (68.3%)                           \<0.001

###### 

Variables associated with anxiety in 196 patients with epilepsy

  Variable                  Subjects with anxiety (N = 76)   Subjects without anxiety (N = 127)   P value on bivariate analysis   Logistic regression p value   Adjusted OR (95% CI)
  ------------------------- -------------------------------- ------------------------------------ ------------------------------- ----------------------------- ----------------------
  Polytherapy               66 (86.8%)                       75 (62.5)                            \<0.001                         0.780                         1.16 (0.40--3.36)
  Carbamazepine             36 (47.4%)                       72 (60%)                             0.057                           0.481                         0.74 (0.32--1.70)
  Topiramate                4 (5.3%)                         0                                    0.022                           0.710                         141.26 (0--9777.0)
  Primidone                 42 (55.3%)                       19 (15.8%)                           \<0.001                         0.023                         2.94 (1.15--7.49)
  Lower educational level   73 (96.1%)                       120 (100%)                           0.028                           0.848                         753.39 (0--2213)
  Depression                59 (77.6%)                       24 (20%)                             \<0.001                         \<0.001                       11.34 (4.92--26.25)
  Poor seizure control      64 (84.2%)                       86 (71.7%)                           0.031                           0.746                         1.17 (0.43--3.16)
  Cryptogenic epilepsy      18 (23.7%)                       52 (43.3%)                           0.005                           0.058                         4.21 (1.57--11.40)
  Posttraumatic epilepsy    14 (18.4%)                       6 (5%)                               0.002                           0.009                         0.21 (0.06--0.68)
